Topoisomerases I and II are nuclear enzymes that play crucial roles in DNA metabolism such as replication, transcription, recombination, repair, chromatin assembly, and chromosome segregation. [1] [2] [3] [4] Due to the crucial role of topoisomerases in the maintenance and replication of DNA during proliferation, cells become highly vulnerable when these functions are lost.
Topoisomerases I and II are nuclear enzymes that play crucial roles in DNA metabolism such as replication, transcription, recombination, repair, chromatin assembly, and chromosome segregation. [1] [2] [3] [4] Due to the crucial role of topoisomerases in the maintenance and replication of DNA during proliferation, cells become highly vulnerable when these functions are lost. 5 Consequently, topo I and II have been attractive targets for design of antitumor agents. 6 It has been reported in our research group α-terpyridine 7, 8 derivatives showed strong cytotoxicities against several human cancer cell lines and considerable topo I and II inhibitory activities. 9 We also studied for topo I and II inhibitory activities of 2,6-dithienyl-4-furylpyridines. 10 From the previous structure-activity relationship studies, we found 2,6-dithienyl-4-furylpyridines exhibited strong topo I and II inhibitory activities as well as strong cytotoxicity against several human cancer cell lines. It would be very interesting to prepare 2,6-dithienyl-4-arylpyridines and evaluate topo I and II inhibitory activities of the prepared compounds. In addition, the comparison of activities between two moieties may provide valuable information for the development of novel antitumor agents. In connection with previous studies, 2,6-dithienyl-4-arylpyridines were prepared and evaluated for their topo I and II inhibitory effects (Figure 1 ).
Experimental Section
Compounds used as starting materials and reagents were purchased from Aldrich Chemical Co., Sigma, Fluka, Junsei and used without further purification. Thin-layer chromatography (TLC) and column chromatography were performed with Kieselgel 60 F 254 (Merck) and silica gel (Kieselgel 60, 230-400 mesh, Merck), respectively. Since all the compounds prepared contain aromatic rings, compounds were visualized and detected on TLC plates with UV light (short wave, long wave, or both). NMR spectra were recorded on a Bruker AMX 250 (250 MHz, FT) for General method for the preparation of 6-23. A mixture of 3 (R 1 = a-c, R 2 = a-g), dry ammonium acetate and 4 (R 3 = a-b) in dry MeOH was heated at 80 o C for 12 to 24 h under nitrogen atmosphere. The solvent was removed by evaporation under reduced pressure, and the residue was diluted with ethyl acetate (100 mL), washed with water (75 mL × 2) and saturated NaCl solution (50 mL). The organic layer was dried with magnesium sulfate and filtered. The filtrate was evaporated at reduced pressure, which was purified by silica gel column chromatography with a gradient elution of ethyl acetate/n-hexane to afford a white solid in 54 to 93% yields. Utilizing the same procedure, eighteen compounds were synthesized. Pharmacology. The topoisomerase I inhibitory activity was carried out as followings: 11 The activity of DNA topoisomerase I was determined by measuring the relaxation of supercoiled DNA pBR322. For measurement of topoisomerase I activity, the reaction mixture was comprised of 35 mM Tris-HCl (pH 8.0), 72 mM KCl, 5 mM MgCl 2 , 5 mM dithiothreitol, 2 mM spermidine, 0.01% bovine serum albumin, 200 ng pBR322, 0. containing of 30% sucrose, 0.5% bromophenol blue and 0.5% xylene cyanol, and subjected to electrophoresis on a 1% agarose gel at 1.5 V/cm for 10 h with a running buffer of Tris-borate-EDTA. Gels were stained for 30 min in a aqueous solution of ethidium bromide (0.5 μg/mL). DNA bands were visualized by transillumination with UV light and supercoiled DNA was quantitated by an image analyzer and LabWork 4.5 software (UVP).
4-(Thiophen

Results and Discussion
Chemistry. Synthetic methods for the preparation of 2,6-dithienyl-4-aryl pyridines (6-23) are summarized in Scheme 1. Acetylthiophenes 1a-c were treated with arylcarboxaldehydes 2a-g in the presence of KOH in methanol-water (5:1), to afford intermediates 3 in a 47-99% yields. Using modified Kröhnke synthesis, 12 2,6-dithienyl-4-arylpyridines were prepared by treatment of 3 with 1-(2-oxo-2-thienylethyl)pyridinium iodide (4a-b) in the presence of ammoniScheme 1 um acetate in methanol to give 6-23 in a 54-93% yields. Pyridinium iodides 4a-b were prepared in a quantitative yield by treatment of 1a-b with iodine in pyridine. Figure 2 shows the prepared 2,6-dithienyl-4-arylpyridines (6-23).
Pharmacology. Wheat germ topoisomerase I and human DNA topoisomerase IIa inhibitory activities 11 for the eighteen prepared 2,6-dithienyl-4-arylpyridines are shown in Figures 3 and 4 , and summarized in Table 1 . Compounds 6-10 exhibited moderate topo I and/or II inhibitory activities.
Especially compound 6 indicates both moderate topo I and II inhibitory activities (33% and 31% inhibition at 100 μM, respectively) and compound 10 has moderate topo I inhibitory activity (35% inhibition at 100 μM). It is generally recognized that those compounds indicate considerable topo I or II inhibitory activities as synthetic compounds, although they have weaker inhibitory activities than those of camptothecin or etoposide. Besides the thienyl derivatives on 4- Notes position, other compounds 11-23 did not show considerable inhibitory activity, which indicate that phenyl or pyridyl derivatives as well as methyl thienyl on 4-position in pyridine ring did not increase the inhibitory activity.
In conclusion, we have designed an efficient synthetic route to prepare eighteen 2,6-dithienyl-4-arylpyridines and evaluated them for their topo I and II inhibitory activity. From structure-activity relationship study, 2,4,6-trithienylpyridines show better inhibitory activities than 2,6-dithienyl-4-phenyl or 2,6-dithienyl-4-pyridylpyridines, but lower inhibitory activities than 2,6-dithienyl-4-furylpyridines. 10 This study may provide valuable information to the researchers who are working on the development of antitumor agents, especially that of topoisomerase I or II inhibitors.
